Analyst firms · Morgan Stanley · NVS
Morgan Stanley NVS price target and rating history
Novartis AG (NVS) · Health Care
Morgan Stanley rates Novartis AG (NVS) Overweight with a $123 price target, as of its latest action on Dec 3, 2025. It has published 5 rating actions on NVS since September 2023, including 3 upgrades and 0 downgrades.
- Current rating
- Overweight
- Price target
- $123
- Median target, all firms
- Too few
- Actions on NVS
- 5
Morgan Stanley price target on NVS
Every Morgan Stanley rating on NVS
- Dec 3, 2025
- Aug 8, 2025
- Feb 12, 2025
- Jan 23, 2024
- Sep 25, 2023
How other firms rate NVS
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Deutsche Bank | Sell | Oct 30, 2026 | |
| HSBC | Hold | Sep 10, 2026 | |
| RBC Capital Markets | Sector Perform | Sep 9, 2026 | |
| Argus Research | Buy | $180 | Mar 11, 2026 |
| Citigroup | Buy | Jan 27, 2026 | |
| Barclays | Equal Weight | Jan 6, 2026 | |
| Morgan Stanley | Overweight | Dec 3, 2025 | |
| BofA Securities | Buy | Nov 25, 2025 |
Questions about Morgan Stanley and NVS
- What is Morgan Stanley's price target for NVS?
- Morgan Stanley's latest stated price target for Novartis AG (NVS) is $123, from its action on Aug 8, 2025.
- What is Morgan Stanley's rating on NVS?
- Morgan Stanley rates NVS Overweight, a bullish rating, as of Dec 3, 2025.
- When did Morgan Stanley last change its view on NVS?
- On Dec 3, 2025, Morgan Stanley upgrades to Overweight from Equal-Weight.
More NVS rating histories
All Morgan Stanley ratingsNVS news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.